Source: GlobalNewswire

Press Release: Replay : Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens

Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens

Read full article »
Replay's Competitors | Replay's News | Replay's Financials
Stay up-to-date with the latest news on Replay
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Lachlan MacKinnon's photo - Co-Founder & CEO of Replay

Co-Founder & CEO

Lachlan MacKinnon

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Replay